{
    "2020-06-22": [
        [
            {
                "time": "2018-01-02",
                "original_text": "The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst Blog",
                        "AbbVie",
                        "Oracle",
                        "GlaxoSmithKline",
                        "Kroger",
                        "Southern"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology",
                        "retail",
                        "utilities"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "medical stocks",
                        "outpaced"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-06-22",
                "original_text": "The Extreme Risks of Trading Your Own Retirement Assets - June 22, 2020",
                "features": {
                    "keywords": [
                        "Extreme Risks",
                        "Trading",
                        "Retirement Assets"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOXÂ® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity",
                "features": {
                    "keywords": [
                        "FDA",
                        "Supplemental Biologics License Application",
                        "BOTOX",
                        "Pediatric Patients",
                        "Neurogenic Detrusor Overactivity"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}